Grifols SA ADR (GRFS)

15.30
+0.36(+2.41%)
After Hours
15.29
-0.01(-0.07%)
- Real-time Data
  • Volume:
    876,426
  • Bid/Ask:
    14.85/15.50
  • Day's Range:
    14.93 - 15.35

GRFS Overview

Prev. Close
14.94
Day's Range
14.93-15.35
Revenue
-
Open
14.93
52 wk Range
14.81-20.49
EPS
-
Volume
876,426
Market Cap
6.41B
Dividend (Yield)
0.66
(4.40%)
Average Vol. (3m)
625,955
P/E Ratio
-
Beta
-
1-Year Change
-20.74%
Shares Outstanding
421,306,554
Next Earnings Date
Jul 29, 2021
What is your sentiment on Grifols SA ADR?
or
Market is currently closed. Voting is open during market hours.

Grifols SA ADR News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuySellStrong Sell
Technical IndicatorsNeutralStrong BuyStrong BuyStrong SellStrong Sell
SummaryNeutralStrong BuyStrong BuyStrong SellStrong Sell

Grifols SA ADR Company Profile

Grifols SA ADR Company Profile

Employees
24000

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.